The new Penn–BioNTech Innovative Therapeutics Seed Fund focuses on transforming Penn biomedical discoveries into venture-backed startups, strengthening Pennsylvania’s life sciences innovation ecosystem from Philadelphia to statewide commercialization networks.
PHILADELPHIA — The University of Pennsylvania, BioNTech SE, and Osage University Partners (OUP) have launched a $50 million venture fund to commercialize Penn-originated biomedical discoveries.
The three organizations, a leading research institution (Penn), a global translational leader (BioNTech), and a specialist investor in university spinouts (OUP), have joined together to increase both the number and quality of life science startups.
Anna Turetsky, PhD, a Penn alum and experienced early-stage biotech investor, was appointed General Partner. Her background in venture investing and building therapeutics companies indicates the fund’s intention to focus on company startup formation rather than participate only in later stages.
The Penn–BioNTech Innovative Therapeutics Seed Fund (PxB Fund) will focus on seed and Series A investments in Penn-founded life science startups, including therapeutics, diagnostics, platforms, research tools, and AI-enabled drug discovery.
Early-stage Penn spinouts that receive local funding are more likely to hire locally, lease lab space in the region, and establish clinical and manufacturing relationships that retain economic value within the state.
Philadelphia-based OUP will manage the fund and currently oversees over $800 million in investments in more than 150 university spinouts, including over 10 from Penn.
Why the PxB Fund matters for the Pennsylvania Innovation Ecosystem
The PxB Fund will accelerate Pennsylvania’s innovation ecosystem by supporting the earliest and most vulnerable stage of life sciences commercialization.
More specialized investors, experienced operators, additional lab space, and downstream partners will be attracted to the area.
Pennsylvania’s life sciences industry is already a heavyweight economic engine—but its companies are disproportionately early-stage and in need of funding.
Life Sciences PA notes that the state’s ecosystem provides about 102,000 direct jobs and supports another ~230,000 jobs through indirect and induced activity, while generating $105.6 billion in total state economic output (with $61.9B direct and $43.7B indirect/induced) based on 2020 estimates.
At the same time, more than 65% of Pennsylvania life sciences establishments have 10 or fewer employees, according to Life Sciences PA.
Founders gain a corporate partner with experience in late-stage translation, offering insights into product profiles, development plans, and partnership dynamics.
A Philadelphia Anchor with Statewide Impact
The Philadelphia area is home to a life sciences cluster, where companies can benefit from the PxB Fund.
According to The Penn Center for Innovation, the Greater Philadelphia market ranked fourth in the U.S. in Colliers’ 2025 life sciences report, consistent with its 2024 ranking.
CBRE, a commercial real estate services and investment firm, reports that in FY2024, the NIH allocated nearly $1.3 billion to Philadelphia organizations for health and life sciences initiatives.
Its Philadelphia market profile showed the region has 11.6 million square feet of lab/R&D space, nearly 55,000 life-science workers, and attracted more than $6.5 billion in life-sciences venture capital from 2019–2024.
Penn highlighted that over the past decade, its research teams contributed to 45 FDA approvals of vaccines and novel treatments, including advances in CAR T-related therapies, and received notable scientific recognition.
Overall
If successful, PxB will bring several benefits to Pennsylvania’s innovation ecosystem, such as more Penn-originated startups funded at formation, increased follow-on investment in the region, and more companies that remain in Philadelphia and Pennsylvania as they grow.
Marc Singer, OUP’s managing partner, cited recent Penn spinouts such as Capstan Therapeutics (acquired by AbbVie) and Interius BioTherapeutics (acquired by Kite) as evidence that Penn-originated science can develop into high-value companies with the appropriate commercialization pathway.
In a market where biotech fundraising cycles can tighten rapidly, new funds are viewed as a real competitive boost to regional innovation.
For Pennsylvania, the key message is not only the $50 million investment, but also the strategic goal of creating a sustainable pipeline that transforms world-class research into venture-backed companies.
This approach supports the state’s innovation ecosystem and accelerates the delivery of new therapies to patients.
